CRSP
Crispr Therapeutics AG
54.20$
-2.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +6.8% | +9.4% | -4.1% | -3.6% | -0.6% | -3.4% | -6.3% | +10.6% | +0.9% | +20.3% | -2.8% | |
| – | +8.4% | +11.1% | -5.2% | -3.3% | -0.3% | -3.6% | -7.2% | +11.3% | +2.4% | +23.9% | -3.1% | |
| – | -26.2% | +81.6% | -31.5% | -53.4% | +32.2% | -21.1% | -16.2% | +47.1% | +22.5% | +19.2% | -31.2% | |
| – | -2.7% | +24.5% | -5.1% | -3.3% | -1.6% | -2.5% | -7.0% | +11.1% | +3.1% | +23.6% | -3.2% | |
| – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | |
| – | -46.7% | -87.5% | – | – | – | – | – | – | – | – | – | |
| – | -3.4% | +2.4% | +1.1% | -11.8% | -2.1% | +8.7% | -5.4% | +3.4% | +4.3% | +165.3% | -0.8% | |
| – | -2.2% | +9.4% | +7.4% | -29.7% | -2.3% | +36.1% | -12.6% | +14.0% | +25.4% | -8.6% | -2.5% | |
| – | +4.2% | +2.3% | +2.9% | +2.6% | +2.4% | +1.3% | +3.0% | +1.3% | +1.8% | +0.2% | +0.2% | |
| – | +45.9% | -56.8% | -42.6% | +64.8% | -5.6% | -11.2% | -25.3% | +21.0% | -5.6% | +22.5% | -17.1% | |
| – | – | – | – | – | – | – | – | – | – | – | +0.1% | |
| – | +9.0% | +10.7% | -4.9% | -2.1% | -0.4% | -5.3% | -6.5% | +12.0% | +0.3% | -5.6% | -3.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.4% | +0.6% | +3.8% | +0.4% | +0.3% | +0.6% | +1.3% | +4.9% | -1.5% | +6.8% | +0.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.